Literature DB >> 16325514

The molecular genetics of breast cancer: the contribution of comparative genomic hybridization.

Jorge S Reis-Filho1, Peter T Simpson, Theodora Gale, Sunil R Lakhani.   

Abstract

Comparative genomic hybridization (CGH) has been the technique of choice over the last 10 years for mapping DNA copy number changes in human tumors. Here we review the literature to demonstrate how CGH has contributed to the comprehension of molecular aspects of breast tumorigenesis. At least two distinct molecular pathways of breast cancer have been characterized that show a strong correlation with histological grade. It seems that grade I invasive ductal carcinomas (IDCs) arise from well-differentiated ductal carcinoma in situ (DCIS), whereas grade III IDCs come from poorly differentiated DCIS. In addition, dedifferentiation from a low- to a high-grade breast cancer has proven an unlikely phenomenon. CGH has been instrumental in dissecting distinct molecular pathways toward breast malignancy and in establishing a direct relationship between genotype and clinical pathological features.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16325514     DOI: 10.1016/j.prp.2005.05.013

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  26 in total

1.  Early Breast Cancer Precursor Lesions: Lessons Learned from Molecular and Clinical Studies.

Authors:  Hans-Peter Sinn; Zeinab Elsawaf; Birgit Helmchen; Sebastian Aulmann
Journal:  Breast Care (Basel)       Date:  2010-08-23       Impact factor: 2.860

2.  Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization.

Authors:  Yuxia Gao; Yun Niu; Xiaowei Wang; Li Wei; Song Lu
Journal:  J Mol Med (Berl)       Date:  2008-10-21       Impact factor: 4.599

3.  Flat epithelial atypia and risk of breast cancer: A Mayo cohort study.

Authors:  Samar M Said; Daniel W Visscher; Aziza Nassar; Ryan D Frank; Robert A Vierkant; Marlene H Frost; Karthik Ghosh; Derek C Radisky; Lynn C Hartmann; Amy C Degnim
Journal:  Cancer       Date:  2015-01-13       Impact factor: 6.860

4.  P-cadherin expression and basal-like subtype in breast cancers.

Authors:  N Liu; Q Yu; T J Liu; Estifanos P Gebreamlak; S L Wang; R J Zhang; J Zhang; Y Niu
Journal:  Med Oncol       Date:  2012-04-01       Impact factor: 3.064

5.  P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.

Authors:  Joana Paredes; Nair Lopes; Fernanda Milanezi; Fernando C Schmitt
Journal:  Virchows Arch       Date:  2006-11-23       Impact factor: 4.064

6.  Factors Associated With Underestimation of Invasive Cancer in Patients With Ductal Carcinoma In Situ: Precautions for Active Surveillance.

Authors:  Carlos Chavez de Paz Villanueva; Valentina Bonev; Maheswari Senthil; Naveenraj Solomon; Mark E Reeves; Carlos A Garberoglio; Jukes P Namm; Sharon S Lum
Journal:  JAMA Surg       Date:  2017-11-01       Impact factor: 14.766

7.  Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ?

Authors:  Lucía Graña-López; Michel Herranz; Inés Domínguez-Prado; Sonia Argibay; Ángeles Villares; Manuel Vázquez-Caruncho
Journal:  Eur Radiol       Date:  2019-08-02       Impact factor: 5.315

Review 8.  [Genome-wide expression profiling as a clinical tool: are we there yet?].

Authors:  F C Geyer; T Decker; J S Reis-Filho
Journal:  Pathologe       Date:  2009-03       Impact factor: 1.011

9.  Molecular classification of breast cancer.

Authors:  Darina Vuong; Peter T Simpson; Benjamin Green; Margaret C Cummings; Sunil R Lakhani
Journal:  Virchows Arch       Date:  2014-05-31       Impact factor: 4.064

10.  High and intermediate grade ductal carcinoma in-situ of the breast: a comparison of pathologic features in core biopsies and excisions and an evaluation of core biopsy features that may predict a close or positive margin in the excision.

Authors:  Oluwole Fadare; Nathan F Clement; Mohiedean Ghofrani
Journal:  Diagn Pathol       Date:  2009-08-19       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.